Q-omics provides the consensus-scored MIR4524B profile across patient tissues and cancer cell-line models. MIR4524B expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR4524B is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MIR4524B RNA expression shows 11,110 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, BRCA, and LSCC as cancer lineages where MIR4524B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4524B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4524B survival associations across molecular data types. MIR4524B RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4524B RNA expression–survival associations across cancer types. High MIR4524B expression shows unfavorable associations in THCA, THYM, LUSC and STAD, but favorable associations in SKCM and LUAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR4524B RNA expression.
This table summarizes MIR4524B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4524B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4524B shows lower tumor expression in BRCA, LUSC, COAD, CHOL and LUAD. The BRCA box plot shows higher MIR4524B RNA expression in normal versus tumor tissue (log2 FC = −1.034, t-test p < 0.001).
This table shows molecular features associated with MIR4524B in patient tissues and cancer cell lines. In patient samples, MIR4524B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
